White labcorp logo

Exciting news: Invitae joins Labcorp to expand the future of genetic testing. Learn more

Genetic testing to inform colorectal cancer care

Hereditary cancer genetic testing can help inform medical management options for your patients with colorectal cancer.1

Start an orderGet in touch
Woman and man staring forward - Invitae colorectal cancer genetic testing
Image of a brunette woman in white shirt - Invitae genetic testing for hereditary cancer

Genetic testing is underutilized in patients with colorectal cancer—despite insurance coverage1

There are more than one million colorectal cancer survivors in the United States, and the majority haven’t undergone hereditary cancer genetic testing.2,3

Image of a bearded man in an olive shirt - Invitae colorectal cancer genetic testing

1 in 9 patients with colorectal cancer may have clinically actionable variants4

Identifying a clinically actionable variant may impact your medical management by informing risk assessment and personalized treatment options.1,5

Invitae genetic testing for hereditary colorectal cancer

We partner with you to integrate genetic testing into your clinic workflow to help increase patient access

  • When patients are referred out to another provider for testing, less than half of those eligible for hereditary cancer genetic testing follow through on submitting test samples.10
  • In a study of young adults (ages 18–49) with colorectal cancer, referral to and attendance at genetic counseling appointments differed by race/ethnicity. Black patients were significantly less likely to be referred to a genetic counselor and less likely to attend appointments compared to Hispanic and White patients.11

Test today for their tomorrow

NCCN=National Comprehensive Cancer Network® (NCCN®)

References

1. Moretz C, et al. JAMA Netw Open. 2022;5(10):e2238167.
2. Hampel H, et al. Cancer Prev Res (Phila). 2011;4(1):1–5.
3. Miller KD, et al. CA A Cancer J Clin. 2022;72(5):409–436.
4. Coughlin SE, et al. JCO Precis Oncol. 2022:e2200517.
5. Samadder NJ, et al. JAMA Oncol. 2021;7(2):230–237.
6. Syngal S, et al. Am J Gastroenterol. 2015;110(2):223–263.
7. Giardiello FM, et al. Am J Gastroenterol. 2014;147(2):502–526.
8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal V.2.2023. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 29, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.4 2023. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 29, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
10. DeFrancesco MS, et al. Obstet Gynecol. 2018;1132(5):1121–1129.
11. Dharwadkar P, et al. Clin Gastroenterol Hepatol. 2022;20(2):353–361.e3.